ExpreS2ion Biotechnologies

www.expres2ionbio.com

ExpreS2ion offers services related to vector development, cell line development incl. RCBs for GMP MCB production, cloning, up- and down-stream development and production of GLP material, as well as licenses to the technology platform.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Medical

INVENSHURE LAUNCHES MEKANISTIC THERAPEUTICS™

Invenshure | June 03, 2022

news image

Venture studio Invenshure announces the launch of MEKanistic Therapeutics, a biotechnology company redefining precision oncology. Co-inventors and pioneers in the MEK inhibitor field, Judith Sebolt-Leopold, PhD, and Christopher Whitehead, PhD, MBA, have rationally designed a drug that blocks two, key pathways (EGFR and PI3K) used to signal cancer cell growth, with a single molecule. In preclinical studies, this first-in-class dual inhibitor shows unparalleled tumor shrinkage without the toxicity...

Read More

Medical

MELINTA THERAPEUTICS PARTNERS WITH BARDA TO ADVANCE TWO FDA-APPROVED ANTIBIOTICS FOR USE IN PEDIATRIC PATIENTS

Businesswire | July 11, 2023

news image

Melinta Therapeutics, LLC a commercial-stage company providing innovative therapies for acute and life-threatening illnesses, announced today a partnership with the Biomedical Advanced Research and Development Authority (BARDA) to advance two antibiotics currently FDA-approved for adults, BAXDELA® (delafloxacin) and VABOMERE® (meropenem and vaborbactam), for use in pediatrics. In addition, Melinta and BARDA will partner on the development of BAXDELA® against biothreat pathogens...

Read More

MedTech, AI

EVAXION PRESENTS PROMISING RESULTS ON EVX-B1, AN AI-DESIGNED VACCINE AGAINST STAPHYLOCOCCUS AUREUS

Globenewswire | August 01, 2023

news image

Evaxion Biotech A/S a clinical-stage biotechnology company specializing in the discovery and development of AI-powered immunotherapies, presents promising results of EVX-B1 at the Staphylococcal Diseases Gordon Research Conference in New Hampshire, USA. “I am excited to present the impressive results of EVX-B1 at the Gordon Research Conference. The demonstration of full disease protection and complete bacterial clearance marks a significant advancement in the fight against...

Read More

Cell and Gene Therapy

SOLVIAS TO PERFORM RELEASE TESTING ON WORLD'S FIRST CRISPR-BASED GENE-EDITING THERAPY

Solvias | January 23, 2024

news image

Solvias, a global provider of chemistry, manufacturing, and control (CMC) analytics, announced that it will perform analytical release testing services on the world's first CRISPR/Cas9 genome-edited cell therapy. The company has signed a long-term agreement with Vertex Pharmaceuticals for CASGEVY™ (exagamglogene autotemcel or exa-cel) which received U.S. Food & Drug Administration (FDA) approval for the treatment of sickle cell disease (SCD) in patients 12 years and older wit...

Read More
news image

Medical

INVENSHURE LAUNCHES MEKANISTIC THERAPEUTICS™

Invenshure | June 03, 2022

Venture studio Invenshure announces the launch of MEKanistic Therapeutics, a biotechnology company redefining precision oncology. Co-inventors and pioneers in the MEK inhibitor field, Judith Sebolt-Leopold, PhD, and Christopher Whitehead, PhD, MBA, have rationally designed a drug that blocks two, key pathways (EGFR and PI3K) used to signal cancer cell growth, with a single molecule. In preclinical studies, this first-in-class dual inhibitor shows unparalleled tumor shrinkage without the toxicity...

Read More
news image

Medical

MELINTA THERAPEUTICS PARTNERS WITH BARDA TO ADVANCE TWO FDA-APPROVED ANTIBIOTICS FOR USE IN PEDIATRIC PATIENTS

Businesswire | July 11, 2023

Melinta Therapeutics, LLC a commercial-stage company providing innovative therapies for acute and life-threatening illnesses, announced today a partnership with the Biomedical Advanced Research and Development Authority (BARDA) to advance two antibiotics currently FDA-approved for adults, BAXDELA® (delafloxacin) and VABOMERE® (meropenem and vaborbactam), for use in pediatrics. In addition, Melinta and BARDA will partner on the development of BAXDELA® against biothreat pathogens...

Read More
news image

MedTech, AI

EVAXION PRESENTS PROMISING RESULTS ON EVX-B1, AN AI-DESIGNED VACCINE AGAINST STAPHYLOCOCCUS AUREUS

Globenewswire | August 01, 2023

Evaxion Biotech A/S a clinical-stage biotechnology company specializing in the discovery and development of AI-powered immunotherapies, presents promising results of EVX-B1 at the Staphylococcal Diseases Gordon Research Conference in New Hampshire, USA. “I am excited to present the impressive results of EVX-B1 at the Gordon Research Conference. The demonstration of full disease protection and complete bacterial clearance marks a significant advancement in the fight against...

Read More
news image

Cell and Gene Therapy

SOLVIAS TO PERFORM RELEASE TESTING ON WORLD'S FIRST CRISPR-BASED GENE-EDITING THERAPY

Solvias | January 23, 2024

Solvias, a global provider of chemistry, manufacturing, and control (CMC) analytics, announced that it will perform analytical release testing services on the world's first CRISPR/Cas9 genome-edited cell therapy. The company has signed a long-term agreement with Vertex Pharmaceuticals for CASGEVY™ (exagamglogene autotemcel or exa-cel) which received U.S. Food & Drug Administration (FDA) approval for the treatment of sickle cell disease (SCD) in patients 12 years and older wit...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us